Symbols

FDMT

4D Molecular·NASDAQ

--(--)

FDMT Profile

4d Molecular Therapeutics, Inc.

A clinical-stage biotherapeutics company that develops therapies for genetic diseases

Industry

Biological Technology

Established Date

03/11/2015

Listing Date

12/11/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

196

Fiscal Year Ends

12-31

Website

www.4dmoleculartherapeutics.com

Security Type

Common stock

Office address

5858 Horton Street #455, Emeryville, CA 94608

Business

Introduction

4D Molecular Therapeutics, Inc., was incorporated under the laws of the State of Delaware on March 11, 2015. The company is a late-stage biotechnology company focused on the development of durable, disease-targeting therapies, and its adeno-associated virus (AAV) vectors are developed using its proprietary Therapeutic Vector Evolution (TVE) platform. The TVE platform uses the principle of directed evolution to generate and screen AAV vectors in non-human primate models that have properties designed to overcome the limitations of traditional AAV and can target disease-related tissues with high unmet need through conventional and local administration routes. 4D's clinical research is mainly focused on vectors developed using the TVE platform for the treatment of retinal and pulmonary disease candidates.